BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 27777139)

  • 1. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8.
    Konuma T; Miyazaki Y; Uchida N; Ohashi K; Kondo T; Nakamae H; Takahashi S; Mori T; Ozawa Y; Kato C; Iwato K; Fukuda T; Ichinohe T; Atsuta Y; Ishiyama K;
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):75-80. PubMed ID: 27777139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8.
    Konuma T; Kondo T; Yamashita T; Uchida N; Fukuda T; Ozawa Y; Ohashi K; Ogawa H; Kato C; Takahashi S; Kanamori H; Eto T; Nakaseko C; Kohno A; Ichinohe T; Atsuta Y; Takami A; Yano S;
    Ann Hematol; 2017 Mar; 96(3):469-478. PubMed ID: 28058493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.
    Heidenreich S; Ziagkos D; de Wreede LC; van Biezen A; Finke J; Platzbecker U; Niederwieser D; Einsele H; Bethge W; Schleuning M; Beelen DW; Tischer J; Nagler A; Glass B; Maertens J; Yáñez L; Beguin Y; Sill H; Scheid C; Stelljes M; Ganser A; Zachée P; Selleslag D; de Witte T; Robin M; Kröger N
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):44-52. PubMed ID: 27720995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
    Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
    Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome.
    Shimomura Y; Hara M; Tachibana T; Ohashi K; Sakura T; Fukuda T; Nakazawa H; Iwato K; Kanda Y; Ikeda T; Eto T; Kanda J; Ichinohe T; Atsuta Y; Ishikawa T; Ishiyama K
    Br J Haematol; 2019 Jul; 186(1):86-90. PubMed ID: 30941758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.
    Armand P; Kim HT; DeAngelo DJ; Ho VT; Cutler CS; Stone RM; Ritz J; Alyea EP; Antin JH; Soiffer RJ
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):655-64. PubMed ID: 17531775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34
    Tamari R; Oran B; Hilden P; Maloy M; Kongtim P; Papadopoulos EB; Rondon G; Jakubowski AA; Andersson BS; Devlin SM; Ahmed S; Popat UR; Ponce D; Chen J; Sauter C; Young JW; de Lima M; Perales MA; O'Reilly RJ; Giralt SA; Champlin RE; Castro-Malaspina H
    Biol Blood Marrow Transplant; 2018 May; 24(5):1079-1087. PubMed ID: 29325829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impact of induced therapy before allogeneic hematopoietic stem-cell transplantation for higher-risk myelodysplastic syndrome: experience of single centre].
    Zhou JY; He GS; Wu DP; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu ZZ; Ma X; Miao M; Xue SL; Wang Y
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3185-8. PubMed ID: 24405537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment CD34
    Jentzsch M; Geus U; Grimm J; Vucinic V; Pönisch W; Franke GN; Behre G; Niederwieser D; Schwind S
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1560-1566. PubMed ID: 30928626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.
    Oran B; Kongtim P; Popat U; de Lima M; Jabbour E; Lu X; Chen J; Rondon G; Kebriaei P; Ahmed S; Andersson B; Alousi A; Ciurea S; Shpall E; Champlin RE
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1618-25. PubMed ID: 24953017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome.
    Itonaga H; Ishiyama K; Aoki K; Aoki J; Ishikawa T; Uchida N; Ohashi K; Ueda Y; Fukuda T; Sakura T; Ohno Y; Iwato K; Okumura H; Kondo T; Ichinohe T; Takanashi M; Atsuta Y; Miyazaki Y
    Ann Hematol; 2019 Jun; 98(6):1367-1381. PubMed ID: 30854574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis.
    Konuma T; Shimomura Y; Ozawa Y; Ueda Y; Uchida N; Onizuka M; Akiyama M; Mori T; Nakamae H; Ohno Y; Shiratori S; Onishi Y; Kanda Y; Fukuda T; Atsuta Y; Ishiyama K;
    Hematol Oncol; 2019 Feb; 37(1):85-95. PubMed ID: 30370627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.
    Mishra A; Anasetti C
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S49-52. PubMed ID: 27521324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.
    Cremers EM; van Biezen A; de Wreede LC; Scholten M; Vitek A; Finke J; Platzbecker U; Beelen D; Schwerdtfeger R; Volin L; Harhalakis N; Blijlevens N; Nagler A; Kröger N; de Witte T
    Ann Hematol; 2016 Dec; 95(12):1971-1978. PubMed ID: 27650829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.